OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Tirzepatide and prevention of chronic kidney disease
Catalina Bosch, Sol Carriazo, María José Soler, et al.
Clinical Kidney Journal (2022) Vol. 16, Iss. 5, pp. 797-808
Open Access | Times Cited: 33

Showing 1-25 of 33 citing articles:

The impact of population ageing on the burden of chronic kidney disease
Nicholas C. Chesnaye, Alberto Ortíz, Carmine Zoccali, et al.
Nature Reviews Nephrology (2024) Vol. 20, Iss. 9, pp. 569-585
Closed Access | Times Cited: 34

Role of the Microbiome in Gut-Heart-Kidney Cross Talk
Griet Glorieux, Sanjay K. Nigám, Raymond Vanholder, et al.
Circulation Research (2023) Vol. 132, Iss. 8, pp. 1064-1083
Closed Access | Times Cited: 35

Effect of tirzepatide on albuminuria levels and renal function in patients with type 2 diabetes mellitus: A systematic review and multilevel meta‐analysis
Paschalis Karakasis, Dimitrios Patoulias, Nikolaos Fragakis, et al.
Diabetes Obesity and Metabolism (2023) Vol. 26, Iss. 3, pp. 1090-1104
Closed Access | Times Cited: 27

Glomerular hyperfiltration as a therapeutic target for CKD
Mehmet Kanbay, Sidar Çöpür, Çiçek Nur Bakır, et al.
Nephrology Dialysis Transplantation (2024) Vol. 39, Iss. 8, pp. 1228-1238
Closed Access | Times Cited: 14

Diabetic Kidney Disease
Anna Gaddy, Mohamed E. Elrggal, Hector Madariaga, et al.
Disease-a-Month (2025), pp. 101848-101848
Closed Access | Times Cited: 1

Interplay of Chronic Kidney Disease and the Effects of Tirzepatide in Patients With Heart Failure, Preserved Ejection Fraction, and Obesity
Milton Packer, Michael R. Zile, Christopher M. Kramer, et al.
Journal of the American College of Cardiology (2025)
Open Access | Times Cited: 1

Cardiometabolic comorbidities and complications of obesity and chronic kidney disease (CKD)
Mariam M. Ali, Sanober Parveen, Vanessa Williams, et al.
Journal of Clinical & Translational Endocrinology (2024) Vol. 36, pp. 100341-100341
Open Access | Times Cited: 7

Comprehensive Cardiovascular and Renal Protection in Patients with Type 2 Diabetes
Almudena Castro Conde, Domingo Marzal Martín, Raquel Campuzano Ruiz, et al.
Journal of Clinical Medicine (2023) Vol. 12, Iss. 12, pp. 3925-3925
Open Access | Times Cited: 12

Considerations for Potential Older Kidney Transplant Candidates with Obesity
John R. Montgomery, Timur Seckin, Nidhi Ghildayal, et al.
Current Transplantation Reports (2025) Vol. 12, Iss. 1
Closed Access

GLP-1 receptor agonists efficacy in managing comorbidities associated with diabetes mellitus: a narrative review
Mahdi Gholami, Narges Zargar Balajam, Samira Rakhsha, et al.
Journal of Diabetes & Metabolic Disorders (2025) Vol. 24, Iss. 1
Closed Access

From Liver to Kidney: The Overlooked Burden of Nonalcoholic Fatty Liver Disease in Chronic Kidney Disease
R. Bogdan, Adrian Boicean, Paula Anderco, et al.
Journal of Clinical Medicine (2025) Vol. 14, Iss. 7, pp. 2486-2486
Open Access

Albuminuria, Forgotten No More: Underlining the Emerging Role in CardioRenal Crosstalk
Gregorio Romero‐González, Néstor Rodríguez, Carles Cañameras, et al.
Journal of Clinical Medicine (2024) Vol. 13, Iss. 3, pp. 777-777
Open Access | Times Cited: 3

Are we ready for an adipocentric approach in people living with type 2 diabetes and chronic kidney disease?
Óscar Moreno, Rebeca Reyes‐García, Inés Modrego Pardo, et al.
Clinical Kidney Journal (2024) Vol. 17, Iss. 4
Open Access | Times Cited: 3

Managing Post-Transplant Diabetes Mellitus after Kidney Transplantation: Challenges and Advances in Treatment
Grzegorz Rudzki, Kinga Knop-Chodyła, Zuzanna Piasecka, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 8, pp. 987-987
Open Access | Times Cited: 3

Is Tirzepatide the New Game Changer in Type 2 Diabetes?
Giuseppe Lisco, Olga Disoteo, Vincenzo De Geronimo, et al.
Endocrines (2024) Vol. 5, Iss. 1, pp. 72-86
Open Access | Times Cited: 2

KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD
Amy K. Mottl, Susanne B. Nicholas
American Journal of Kidney Diseases (2023) Vol. 83, Iss. 3, pp. 277-287
Closed Access | Times Cited: 6

Improving glycemic control: transitioning from dulaglutide to tirzepatide in patients with type 2 diabetes undergoing hemodialysis
Emiko Otsuka, Mineaki Kitamura, Satoshi Funakoshi, et al.
Frontiers in Pharmacology (2024) Vol. 15
Open Access | Times Cited: 2

The use of semaglutide in patients with renal failure- a retrospective cohort study
Jane J. Long, Sukhdeep Sahi, Adley Lemke, et al.
Endocrine Practice (2024) Vol. 30, Iss. 10, pp. 963-969
Closed Access | Times Cited: 2

Glucagon-like peptide-1 (GLP-1) receptor agonists for weight management: A review for the gynecologic oncologist
Courtney J. Riedinger, Julia Sakach, Jill M. Maples, et al.
Gynecologic Oncology (2024) Vol. 190, pp. 1-10
Closed Access | Times Cited: 2

GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Daria Abasheva, Alberto Ortíz, Beatriz Fernández‐Fernández
Clinical Kidney Journal (2024) Vol. 17, Iss. Supplement_2, pp. 19-35
Open Access | Times Cited: 2

Novel pharmacological interventions for diabetic kidney disease
Seng Kiong Tan, Jairo A Pinzón-Cortés, Mark E. Cooper
Current Opinion in Nephrology & Hypertension (2023) Vol. 33, Iss. 1, pp. 13-25
Closed Access | Times Cited: 5

A Brain Reward Circuit Inhibited By Next-Generation Weight Loss Drugs
Elizabeth Godschall, Taha Buğra Güngül, Isabelle R. Sajonia, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1

Optimization of potassium management in patients with chronic kidney disease and type 2 diabetes on finerenone
Alberto Ortíz, Roberto Alcázar Arroyo, Pedro Pablo Casado Escribano, et al.
Expert Review of Clinical Pharmacology (2023) Vol. 16, Iss. 6, pp. 519-531
Closed Access | Times Cited: 3


Salvador Pedraza, Arturo Armiñana, Celia Montón-Gómez, et al.
ANALES RANM (2023) Vol. 140, Iss. 140(02)
Open Access | Times Cited: 3

Page 1 - Next Page

Scroll to top